Risk of SARS-CoV-2 infection in patients with hematologic diseases receiving tixagevimab/cilgavimab as pre-exposure prophylaxis in most recent Omicron sublineages era

Although the overall mortality during SARS-CoV-2 Omicron variants of concern (VoC) wave might be lower than that seen with other previous VoCs immunocompromised individuals remain at increased the risk of hospitalization and prolonged duration of the infection compared to the general population [1]. Moreover, persons with immunosuppression may experience reduced vaccine immune response with an impaired seroconversion and effectiveness [2]. To address the need to protect these individuals from breakthrough infections and possibly from long-lasting SARS-CoV-2 infections, in December 2021 the combination tixagevimab/cilgavimab (EvusheldTM, AstraZeneca; T/C) received the emergency use authorization (EUA) from the United States Food and Drug Administration (FDA) as pre-exposure prophylaxis (PrEP) at the dosage of 150/150 mg in moderate to severely immunocompromised individuals (aged 12 years or older and weighing>40 kg) who could not be vaccinated against COVID-19 or who may have had an inadequate response to SARS-CoV-2 vaccination.
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Tags: Short Communication Source Type: research